Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941095 | 0.84 | CTSK (0.39) | CTSKMEN1GAAKMT2ACHRNB2 | |
| SCHEMBL21974201 | 0.83 | CTSK (0.38) | CTSKMEN1GAAKMT2ACHRNB2 | |
| SCHEMBL3775087 | 0.83 | CTSK (0.37) | CTSKMEN1GAAKMT2ACHRNB2 | |
| SCHEMBL16517171 | 0.83 | CTSK (0.37) | CTSKMEN1GAAKMT2ACHRNB2 | |
| SCHEMBL17898137 | 0.82 | MEN1 (0.34) | GABRR1CYP1A2CTSKMEN1GAA | |
| SCHEMBL3711368 | 0.82 | CTSK (0.38) | CTSKMEN1GAAKMT2ACHRNB2 | |
| SCHEMBL10473405 | 0.82 | MEN1 (0.34) | GABRR1CYP1A2CTSKMEN1GAA | |
| SCHEMBL21918067 | 0.82 | CHRNB2 (0.36) | CYP1A2CTSKGAACHRNB2CHRNB4 | |
| SCHEMBL31169968 | 0.81 | CTSK (0.34) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26272251 | 0.81 | CTSK (0.34) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| WO-2021197452-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | 上海翰森生物医药科技有限公司 | 2021-10-07 | — | — | WO | disclosed |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2020-11-24 | — | — | US | disclosed |
| WO-2019079626-A1 | 6-(5-MEMBERED HETEROARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
| US-9902736-B2 | 1-oxo/acylation-14-acylated oridonin derivative, preparation method therefor and application thereof | HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| CN-101827838-A | Cannabinoid receptor ligand | ASTRAZENECA AB | 2010-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355105-A1 | REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | PTPN11, PTPN1, PTPN7 | GABRR1 916/4885CYP1A2 1674/4885CTSK 4866/4885 |
| US-10844079-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | GABRR1 1871/4885CYP1A2 1444/4885CTSK 4166/4885 |
| US-20230134869-A1 | CRYSTAL FORM OF FREE ALKALI OF NITROGEN-CONTAINING AROMATIC DERIVATIVES | PTPN22, PTPN2, PTPN5 | GABRR1 3025/4885CYP1A2 1264/4885CTSK 4770/4885 |
| US-11685748-B2 | Spiro aromatic ring compound and application thereof | PTPN1, PTPN11, PTPN5 | GABRR1 1871/4885CYP1A2 1444/4885CTSK 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.